With Taxotere (Docetaxel) and Jevtana (Cabazitaxel) both originally developed and patented by Sanofi, it would not be surprising to see an offer. Both drugs while old are still standard chemotherapy treatments and versions which do not rash the immune system of the patients along the way would certainly be attractive.
What we do not know of course is what else they have in the lab. We do not even know if they are one of the undisclosed conjugate players. I originally thought they were but have had increasing doubt in recent times.
But a very plausible theory AB and no-one knows these drugs better.
With Taxotere (Docetaxel) and Jevtana (Cabazitaxel) both...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.5¢ |
Change
-0.003(3.06%) |
Mkt cap ! $39.17M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.5¢ | $12.55K | 130.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 586785 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 56840 | 1 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |